Drugs / ETH47
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07055321 | Nov 2023 → Jul 2024 | — | Ethris GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07059767 | Jun 2025 → Jun 2026 overdue | asthma | Ethris GmbH | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-01-30 | Ethris GmbH | Results Ethris Presents Positive Topline Phase 1 Data with mRNA Lead Candidate ETH47 for Uncontrolled Asthma ethris.com ↗ |
| 2024-06-25 | Ethris GmbH | Results Ethris Announces Positive Initial Phase 1 Data Demonstrating Nasal Delivery of mRNA Lead Candidate ETH47 ethris.com ↗
Ethris GmbH , a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today preliminary positive data from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, and target engagement of lead mRNA candidate ETH47 encoding interferon lambda (IFNλ), in healthy participants. |
| 2023-11-28 | Ethris GmbH | Regulatory ETHRIS Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class inhaled mRNA for Respiratory Viral Infections ethris.com ↗
Ethris GmbH , a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETH47 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07059767 ↗ |
| Route | Intranasal | “single intranasal administration” NCT07055321 ↗ |